Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-met inhibitor SU11274 in human lung cancer A549 cells

Journal of Pharmacological Sciences

Volumn 118, Issue 4, 2012, Pages 423-432

  Liu, Ying ^a   Yang, Ying ^a   Ye, Yuan Chao ^a   Shi, Qi Feng ^a   Chai, Kuan ^a   Tashiro, Shin Ichi ^b   Onodera, Satoshi ^b   Ikejima, Takashi ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Autophagy; Bcl 2; c Met; ERK; SU11274

Indexed keywords

BECLIN 1; MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN BCL 2; PROTEIN P53; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84864643231     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11181FP     Document Type: Article

References (47)

1. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29:78-86.
2. Li L, He D, Yang J, Wang X. Cordycepin inhibits renal interstitial myofibroblast activation probably by inducing hepatocyte growth factor expression. J Pharmacol Sci. 2011;117:286-294.
3. Francesca DB, Michela F, Andrea R. Receptor tyrosine kinases as targets for cancer therapy. Cancer Ther. 2004;20:317-328.
4. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 2010;68:198-203.
5. Wader KF, Fagerli UM, Holt RU, Stordal B, Borset M, Sundan A, et al. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur J Haematol. 2008;81:380-383.
6. Moon WS, Park HS, Yu KH, Park MY, Kim KR, Jang KY, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol. 2006;3:1324-1332.
7. Tomiya T, Nishikawa T, Inoue Y, Ohtomo N, Ikeda H, Tejima K, et al. Leucine stimulates HGF production by hepatic stellate cells through mTOR pathway. Biochem Biophysl Res Commun. 2007;358:176-180.
8. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998;10:404-410.
9. Mahtouk K, Tjin EP, Spaargaren M, Pals ST. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta. 2010;1806:208-219.
10. Zimmer Y, Vaseva AV, Medova M, Streit B, Blank-Liss W, Greiner RH, et al. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer Lett. 2010;289:228-236.
11. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463-477.
12. Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and β4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 2008; 226:178-191.
13. Duan WJ, Jin XY, Li QS, Tashiro S, Onodera S, Ikejima T. Silibinin induced autophagic and apoptotic cell death in HT1080 cells through a reactive oxygen species pathway. J Pharmacol Sci. 2010;113:48-56.
14. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ ERK signal pathway. J Pharmacol Sci. 2007;103:56-66.
15. Ye YC, Yu L, Wang HJ, Tashiro S, Onodera S, Ikejima T. TNFα-induced necroptosis and autophagy via supression of the p38-NF-κB survival pathway in L929 cells. J Pharmacol Sci. 2011; 117:160-169.
16. Xu S, Zhao Y, Yu L, Shen X, Ding F, Fu G. Rosiglitazone attenuates endothelial progenitor cell apoptosis induced by TNF-α via ERK/MAPK and NF-κB signal pathways. J Pharmacol Sci. 2011; 117:265-274.
17. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci. 2008;107:370-379.
18. Klionsky DJ. The molecular machinery of autophagy: unanswered questions. Cell Sci. 2005;118:7-18.
19. Kanzawa T, Kondo Y, Ito H. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63:2103-2108.
20. Kessel D, Reiners JJ Jr, Hazeldine ST, Polin L, Horwitz JP. The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents XK469 and SH80. Mol Cancer Ther. 2007;6:370-379.
21. Yu Y, Chiba Y, Sakai H, Misawa M. Possible involvements of nuclear factor-κB and activator protein-1 in the tumor necrosis factor-α-induced upregulation of matrix metalloproteinase-12 in human alveolar epithelial A549 cell line. J Pharmacol Sci. 2010; 112:83-88.
22. Zeng J, Xia S, Zhong W, Li J, Lin L. In vitro and in vivo effects of ketamine on generation and function of dendritic cells. J Pharmacol Sci. 2011;117:170-179.
23. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27-42.
24. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3:542-545.
25. Wang HJ, Tashiro SI, Onodera S, Ikejima T. Inhibition of insulin-like growth factor 1 receptor signaling enhanced silibinin-induced activation of death receptor and mitochondrial. J Pharmacol Sci. 2008;3:260-269.
26. Pushparai PN, Melendez AJ. Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. Clin Exp Pharmacol Physiol. 2006;33:504-510.
27. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927-939.
28. Wang ZH, Xu L, Duan ZL, Zeng LQ, Yan NH, Peng ZL. Beclin 1-mediated macroautophagy involves regulation of caspase-9 expression in cervical cancer HeLa cells. Gynecol Oncol. 2007;107:107-113.
29. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999;5:662-668.
30. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and its prognostic significance. Jpn J Cancer Res. 1996;87:1063-1069.
31. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg. 1998;6:1915-1918.
32. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1-26.
33. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Jeffrey PL, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;11:7345-7355.
34. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through anti-proliferative and antiangiogenic mechanisms. Cancer Res. 2007;9:4408-4417.
35. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007;8:3529-3534.
36. Underiner TL, Herbertz T, Miknyoczki SJ. Discovery and development of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med Chem. 2010;10:7-27.
37. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. PNAS. 2004;101:17198-17203.
38. Moon WS, Park HS, Yu KH, Park MY, Kim KR, Jang KY, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol. 2006;3:1324-1332.
39. Gobert Gosse S, Bourqin C, Liu WQ, Garbay C, Mouchiround G. M-CSF stimulated differentiation requires persistent MEK activity and MAPK phosphorylation independent of Grb2-Sos association and phosphatidylinositol 3-kinase activity. Cell Signal. 2005;11:1352-1362.
40. Suzuki K, Hino M, Kutsuna H. Selective activation of p38 mitogen-activated protein kinase cascade in human eutrophils stimulated by IL-1β. J Immol Lunol. 2001;167:5940-5947.
41. Pierre S, Bats AS, Coumoul X. Understanding SOS (Son of Sevenless). Biochem Pharmacol. 2011;9:1049-1056.
42. Yang SJ, Chang SC, Wen HC, Chen CY, Liao JF, Chang CH. Plumbagin activates ERK1/2 and Akt via superoxide, Src and PI3-kinase in 3T3-L1 cells. Eur J Pharmacol. 2010;638:21-28.
43. Francesca DB, Michela F, Andrea R. Receptor tyrosine kinases as targets for cancer therapy. Cancer Ther. 2004;2:317-328.
44. Singh S, Upadhyay AK, Ajay AK, Bhat MK. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcimoma: a novel target of p53 in apoptosis. FEBS Lett. 2007;581: 289-295.
45. Nakata K, Suzuki Y, Inoue T, Ra C, Yakura H, Mizuno K. Deficiency of SHP1 leads to sustained and increased ERK activation in mast cell, thereby inhibiting IL-3-dependent proliferation and cell death. Mol Immunol. 2011;48:472-480.
46. Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A. 2006;103:4952-4957.
47. Zalckvar E, Berissi H, Mizrachy L, Idelchuk Y, Koren I, Eisenstein M, et al. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep. 2009;10:285-292.